Harmony Biosciences

HRMY · Nasdaq · United States

Share price · HRMY

$33.11-5.72 (-14.73%) 3M

close as of 2026-11-18 · 24h delayed · vol 566K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when HRMY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-7.0%
  2. 22 Oct 2026-6.0%
  3. 4 Aug 2026+8.9%
  4. 21 Jul 2026+10.0%
  5. 10 Jun 2026+4.0%
  6. 21 Apr 2026+8.8%
  7. 23 Feb 2026-7.9%
  8. 20 Feb 2026-15.2%
  9. 18 Feb 2026-4.4%

    Nothing announced by HRMY that day or the session before.

  10. 13 Jan 2026-6.6%

Share of unusual movement by asset

For each asset, the share of HRMY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Pitolisant (Wakix) (Wakix)
events and moves
4shown from 8 days
Clemizole (EPX-100)
events and moves
1shown from 8 days
Pitolisant GR
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—52%

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
7Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Histamine H3 receptor (antagonist / inverse agonist)Small molecule
Myotonic Dystrophy Type 1NarcolepsyIdiopathic HypersomniaPrader-Willi Syndrome
Phase 3
Histamine H1 receptor · Serotonin receptors (5-HT)Small molecule
EpilepsyDravet SyndromeLennox-Gastaut Syndrome
Preclinical / Unstaged
Histamine H3 receptor (antagonist / inverse agonist)Small molecule
Narcolepsy

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (2)
Pitolisant (Wakix)Phase 3Prader-Willi Syndrome
Est. primary completion 2027-04 · NCT06366464 · CT.gov ↗
What to watch
Clemizole (EPX-100)Phase 3Dravet Syndrome
Est. primary completion 2027-04 · NCT04462770 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Pitolisant (Wakix)Phase 3Prader-Willi Syndrome
Est. primary completion 2030-08 · NCT07219485 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 April 2027FDA action datePitolisant GRPDUFA date for the Pitolisant GR NDA
US, FDA · Source ↗

Recent

4 November 2026Filing acceptedPitolisant GRFDA accepts NDA for Pitolisant GR
US, FDA · Source ↗
September 2026ApprovalPitolisant (Wakix)Wakix approved in Japan for narcolepsy and OSAS-associated sleepiness
JP, MHLW · Viatris · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$269M$72M$647M+ $124M short-term inv.—$77M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$261M$47M$550M+ $118M short-term inv.—$92M operating cash flowreport ↗
2026-Q1$215M$69M$590M+ $52M short-term inv.—$28M operating cash flowreport ↗
2025-Q3$239M$55M$647M+ $26M short-term inv.—$109M operating cash flowreport ↗
2025-Q2$200M$50M$546M+ $19M short-term inv.—$79M operating cash flowreport ↗
2025-Q1$185M$35M$489M+ $18M short-term inv.—$34M operating cash flowreport ↗
2024-Q3$186M$25M$388M+ $23M short-term inv.—$71M operating cash flowreport ↗
2024-Q2$173M$64M$318M+ $30M short-term inv.—$43M operating cash flowreport ↗
2024-Q1$155M$22M$333M+ $39M short-term inv.—$31M operating cash flowreport ↗
2023-Q3$160M$18M$325M+ $46M short-term inv.—$63M operating cash flowreport ↗
2023-Q2$134M$15M$318M+ $54M short-term inv.—$37M operating cash flowreport ↗
2023-Q1$119M$13M$289M+ $56M short-term inv.—$43M operating cash flowreport ↗
2022-Q3$117M$41M$262M+ $46M short-term inv.—$55M operating cash flowreport ↗
2022-Q2$107M$13M$237M+ $18M short-term inv.—$34M operating cash flowreport ↗
2022-Q1$85M$7.6M$225M—$29M operating cash flowreport ↗
2021-Q3$81M$12M$190M$9.6M$30M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$868M$190M$753M+ $23M short-term inv.—$348M operating cash flowreport ↗

Harmony Biosciences reported full-year 2025 revenue of $868.45M, up 21.5% YoY, with R&D spend of $189.59M, up 30.0% YoY. The company ended the period with cash and equivalents of $752.77M and reported net income of $158.69M.

The company reiterated 2026 WAKIX net revenue guidance of $1.0–$1.04 billion. It completed settlements with three additional generic filers, bringing total settled ANDA filers to six of seven, and received FDA approval for the pediatric cataplexy indication in February. Pitolisant GR NDA submission remains on track for Q2 2026, Phase 3 topline data for pitolisant in Prader-Willi syndrome is expected in 2H 2026, the orexin-2 agonist (BP1.15205) Phase 1 trial is ongoing with data expected in mid-2026, and EPX-100 Phase 3 trials in Dravet syndrome and Lennox-Gastaut syndrome have topline data anticipated in 1H 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$715M$146M$453M+ $14M short-term inv.—$220M operating cash flowreport ↗
2023-FY$582M$76M$312M+ $42M short-term inv.—$219M operating cash flowreport ↗
2022-FY$438M$71M$245M+ $79M short-term inv.—$144M operating cash flowreport ↗
2021-FY$305M$30M$235M—$99M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($6.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-18Budur Kumar · CHIEF MEDICAL OFFICEROption exercise10,406$30.69$319KForm 4
2026-09-18Budur Kumar · CHIEF MEDICAL OFFICEROption exercise25,446$30.27$770KForm 4
2026-09-18Budur Kumar · CHIEF MEDICAL OFFICEROpen-market sale35,852$43.05$1.5MForm 4
2026-09-18Budur Kumar · CHIEF MEDICAL OFFICEROption exercise (derivative)10,406——Form 4
2026-09-18Budur Kumar · CHIEF MEDICAL OFFICEROption exercise (derivative)25,446——Form 4
2026-09-17Budur Kumar · CHIEF MEDICAL OFFICEROption exercise400$30.69$12KForm 4
2026-09-17Budur Kumar · CHIEF MEDICAL OFFICEROption exercise400$30.27$12KForm 4
2026-09-17Budur Kumar · CHIEF MEDICAL OFFICEROpen-market sale800$43.00$34KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 308 reporting institutions held 55.6M shares ($1.4B, 94.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.7,070,035$198.0M
2FMR LLC3,157,639$88.4M
3VANGUARD PORTFOLIO MANAGEMENT LLC2,714,353$76.0M
4AMERICAN CENTURY COMPANIES INC2,105,179$59.0M
5VANGUARD CAPITAL MANAGEMENT LLC2,102,315$58.9M
6DIMENSIONAL FUND ADVISORS LP2,076,510$58.2M
7STATE STREET CORP1,784,362$50.0M
8ARMISTICE CAPITAL, LLC1,624,000$45.5M
9ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1,382,113$38.7M
10GEODE CAPITAL MANAGEMENT, LLC1,322,720$37.1M
11GOLDMAN SACHS GROUP INC1,239,207$34.7M
12RENAISSANCE TECHNOLOGIES LLC1,077,371$30.2M
13MORGAN STANLEY1,031,018$28.9M
14MILLENNIUM MANAGEMENT LLC954,359$26.7M
15JPMORGAN CHASE & CO823,513$22.2M